These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30347144)

  • 1. Impact of Dengue Virus Serotype 2 Strain Diversity on Serological Immune Responses to Dengue.
    Keasey SL; Smith JL; Fernandez S; Durbin AP; Zhao BM; Ulrich RG
    ACS Infect Dis; 2018 Dec; 4(12):1705-1717. PubMed ID: 30347144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.
    Uno N; Ross TM
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33208445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dengue Virus Serotype 1 Conformational Dynamics Confers Virus Strain-Dependent Patterns of Neutralization by Polyclonal Sera.
    VanBlargan LA; Milutinovic PS; Goo L; DeMaso CR; Durbin AP; Whitehead SS; Pierson TC; Dowd KA
    J Virol; 2021 Nov; 95(23):e0095621. PubMed ID: 34549976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing and enhancing antibody responses to five genotypes of dengue virus type 1 (DENV-1) in DENV-1 patients.
    Yamanaka A; Moi ML; Takasaki T; Kurane I; Konishi E
    J Gen Virol; 2017 Feb; 98(2):166-172. PubMed ID: 27911254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
    Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
    J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of Surface Display of DENV2 E Protein on a Nanoparticle to Induce Virus Specific Neutralizing Antibody Responses.
    Coffman JE; Metz SW; Brackbill A; Paul M; Miley MJ; DeSimone J; Luft JC; de Silva A; Tian S
    Bioconjug Chem; 2018 May; 29(5):1544-1552. PubMed ID: 29701995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
    Khanam S; Pilankatta R; Khanna N; Swaminathan S
    Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses.
    Metz SW; Tian S; Hoekstra G; Yi X; Stone M; Horvath K; Miley MJ; DeSimone J; Luft CJ; de Silva AM
    PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005071. PubMed ID: 27764114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity.
    Chen RE; Smith BK; Errico JM; Gordon DN; Winkler ES; VanBlargan LA; Desai C; Handley SA; Dowd KA; Amaro-Carambot E; Cardosa MJ; Sariol CA; Kallas EG; Sékaly RP; Vasilakis N; Fremont DH; Whitehead SS; Pierson TC; Diamond MS
    Cell Host Microbe; 2021 Nov; 29(11):1634-1648.e5. PubMed ID: 34610295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
    J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
    Osorio JE; Wallace D; Stinchcomb DT
    Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques.
    Raviprakash K; Apt D; Brinkman A; Skinner C; Yang S; Dawes G; Ewing D; Wu SJ; Bass S; Punnonen J; Porter K
    Virology; 2006 Sep; 353(1):166-73. PubMed ID: 16814355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Molecular Specificity of the Human Antibody Response to Dengue Virus Infections.
    Gallichotte EN; Baric RS; de Silva AM
    Adv Exp Med Biol; 2018; 1062():63-76. PubMed ID: 29845525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tracking the polyclonal neutralizing antibody response to a dengue virus serotype 1 type-specific epitope across two populations in Asia and the Americas.
    Andrade DV; Warnes C; Young E; Katzelnick LC; Balmaseda A; de Silva AM; Baric RS; Harris E
    Sci Rep; 2019 Nov; 9(1):16258. PubMed ID: 31700029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct and indirect interactions in the recognition between a cross-neutralizing antibody and the four serotypes of dengue virus.
    Lisova O; Belkadi L; Bedouelle H
    J Mol Recognit; 2014 Apr; 27(4):205-14. PubMed ID: 24591178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction and preliminary investigation of a novel dengue serotype 4 chimeric virus using Japanese encephalitis vaccine strain SA14-14-2 as the backbone.
    Li Z; Yang H; Yang J; Lin H; Wang W; Liu L; Zhao Y; Liu L; Zeng X; Yu Y; Li Y
    Virus Res; 2014 Oct; 191():10-20. PubMed ID: 25091563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.